Balloon-expandable transcatheter aortic valve implantation with or without predilation – results of a meta-analysis of 3 multicenter registries

Jannik Ole Ashauer, Nikolaos Bonaros, Markus Kofler, Gerhard Schymik, Christian Butter, Mauro Romano, Vinayak Bapat, Justus Strauch, Holger Schröfel, Andreas Busjahn, Cornelia Deutsch, Peter Bramlage, Jana Kurucova, Martin Thoenes, Stephan Baldus, and Tanja K. Rudolph

Abstract
Background: To evaluate the outcomes of transcatheter aortic valve implantation (TAVI) without balloon aortic valvuloplasty (BAV) in a real-world setting through a patient-level meta-analysis.

Methods: The meta-analysis included patients of three European multicenter, prospective, observational registry studies that compared outcomes after Edwards SAPIEN 3 or XT TAVI with (n = 339) or without (n = 355) BAV. Unadjusted and adjusted pooled odds ratios (with 95% confidence intervals) were calculated for procedural and 30-day outcomes.

Results: Median procedural time was shorter in the non-BAV group than in the BAV group (73 versus 93 min, p = 0.001), as was median fluoroscopy time (7 versus 11 min, p = 0.001). Post-delivery balloon dilation (15.5% versus 22.4%, p = 0.02) and catecholamine use (9.0% vs. 17.9%; p = 0.016) was required less often in the non-BAV group than in the BAV group with the difference becoming insignificant after multiple adjustment. There was a reduced risk for periprocedural atrioventricular block during the intervention (1.4% versus 4.1%, p = 0.035) which was non-significant after adjustment. The rate of moderate/severe paravalvular regurgitation post-TAVI was 0.6% in the no-BAV group versus 2.7% in the BAV group. There were no between-group differences in the risk of death, stroke or other adverse clinical outcomes at day 30.

Conclusions: This patient-level meta-analysis of real-world data indicates that TAVI performed without BAV is advantageous as it has an adequate device success rate, reduced procedure time and no adverse effects on short-term clinical outcomes.

Keywords: Transcatheter aortic valve implantation, Balloon aortic valvuloplasty, Pre-dilation, Aortic stenosis

Background
The conventional approach for transcatheter aortic valve implantation (TAVI) includes predilation balloon aortic valvuloplasty (BAV) to help estimate prosthetic valve size, facilitate delivery of the TAVI catheter across the valve, optimize positioning and expansion of the prosthetic valve [1–4]. BAV can also be associated with adverse effects, however, such as hemodynamic instability, arrhythmia necessitating permanent pacemaker implantation, embolic events and stroke [1, 4–8]. Consequently, TAVI is increasingly being performed without BAV [9, 10]. Clinical studies of TAVI without BAV (direct TAVI) have provided encouraging pivotal results [11, 12]. Several subanalyses of larger registry studies later also suggested that direct TAVI is associated with good procedural results and clinical outcomes [9, 10, 13, 14]. To explore this topic further for balloon expandable valves is important for the following reasons: 1) Penetration of the calcified aortic valves is more cumbersome with balloon-expandable than with self-expanding valves due to the balloon and the annular skirt; 2) After successful implantation there is decreased need for post-implant dilatation (circular shape of the valve, lower rates...
of PV-leaks); 3) A limited balloon inflation can facilitate smooth introduction of the valve into the annulus.

To address this lack of data, three prospective, multicenter, registry studies evaluated TAVI using the balloon-expandable Edwards SAPIEN prosthetic valves, with and without BAV, and found that direct TAVI was feasible, safe and provided adequate efficacy in a real-world setting [15–17] (Schymik G, Rudolph TK, Jacobshagen C, Rothe J, Treede H, Kerber S, Frank D, Sykorova L, Okamoto M, Thoenes M, et al. Balloon-expandable transfemoral transcatheter aortic valve implantation with or without predilation – findings from the EASE-IT TF multicentre registry, submitted). A meta-analysis of these three studies has now been conducted to provide additional information on the use of TAVI without BAV in a real-world setting.

Methods
Study characteristics
All three studies included in the meta-analysis were multicenter, prospective, observational registry studies conducted under the guidance of the Institute for Pharmacology and Preventive Medicine (Cloppenburg, Germany). Full details of the design and methodology for each study have been reported previously [18–20]. EASE-IT TF recruited patients undergoing transfemoral (TF) TAVI from 10 sites in Germany [19], EASE-IT TA recruited patients undergoing transapical (TA) TAVI from 10 sites in Germany as well [20], and ROUTE enrolled patients undergoing transaortic (TAo) TAVI from 18 sites across Europe [18]. Edwards SAPIEN 3 [18–20] or XT [18] transfemoral prosthetic heart valves were used in all studies. Patients were aged ≥18 years and had an indication for TAVI as evaluated by the center-specific heart team. Decisions about whether or not to perform BAV predilation were made at the discretion of the treating physicians and were independent of inclusion in the registry. The individual studies enrolled between 196 and 300 evaluable patients [15–17] (Schymik G, Rudolph TK, Jacobshagen C, Rothe J, Treede H, Kerber S, Frank D, Sykorova L, Okamoto M, Thoenes M, et al. Balloon-expandable transfemoral transcatheter aortic valve implantation with or without predilation – findings from the EASE-IT TF multicentre registry, submitted).

All three studies assessed outcomes at the time of the procedure and after 30 days, with the primary endpoints being composite safety endpoints (using definitions based on the Valve Academic Research Consortium-2 consensus document) at 30 days [21]. EASE-IT TF and EASE-IT TA had a 6 months follow-up, while ROUTE had no 6 months, but a 1 year follow-up.

Data extraction
For the meta-analysis, data on patient and disease characteristics, procedural details and outcomes, and longer-term outcomes were extracted. Procedural details and outcomes included: device success, post-delivery balloon dilation, procedural time, fluoroscopy time, contrast agent volume, hemodynamic instability and inotropic support (both were not available for ROUTE), transvalvular pressure gradient and periprocedural complications. Longer-term outcomes included: mortality, stroke, non-fatal myocardial infarction, new-onset dialysis, acute kidney failure, permanent pacemaker implantation, life-threatening bleeding, major vascular complications, hospitalization, valve dysfunction, New York Heart Association (NYHA) class III or IV, and Canadian Cardiovascular Society Grading of Angina Pectoris class III or IV.

Statistical analysis
Pooled data were compared between the group who underwent TAVI with BAV and the group who underwent TAVI without BAV. Unadjusted and adjusted pooled odds ratios (with 95% confidence intervals) were calculated for procedural outcomes and longer-term outcomes. Components of the composite safety endpoints used in the original studies were analyzed individually in the meta-analysis. Procedural and 30-day outcomes were also presented according to the access route used (TF, TA or TAo) with odds ratios (and 95% CI) for patients who did or did not undergo BAV. All statistical analyses were carried out using R version 3.4.3 (2017-11-30) [22], with a p-value of < 0.05 considered significant.

Results
The pooled analysis population (n = 694) comprised 339 patients who underwent TAVI with BAV (including 56 TF, 61 TA and 222 TAo) and 355 who underwent TAVI without BAV (including 140 TF, 137 TA and 78 TAo).

Baseline patient details
Baseline patient characteristics are summarized in Table 1. Those in the no-BAV group had a higher median bodyweight (75 versus 72 kg, p = 0.027) and body surface area (1.84 versus 1.81 cm², p = 0.032) than those in the BAV group. A large proportion of patients in both groups had coronary artery disease and/or had undergone a prior cardiovascular intervention. Patients in the no-BAV group were less likely to have peripheral artery disease (23.9% versus 43.4%, p = 0.001) and more likely to have had a prior cardiovascular intervention (44.8% versus 36.3%, p = 0.025) compared with the BAV group, and had a higher median EuroSCORE II score (5 versus 4, p = 0.005). Aortic valve disease characteristics were similar in both groups.

Periprocedural details
The most commonly used valve size in both groups was 26 mm (Table 2). Post-delivery balloon dilation was required less often in the no-BAV group than in the BAV
Although the unadjusted odds ratio supported a reduced risk in the no-BAV group (OR 0.63, 95% CI 0.43–0.93), this was no longer significant in the adjusted analysis (aOR 0.67, 95% CI 0.41–1.06) (Table 3). Median total procedural time was significantly shorter in the no-BAV group compared with the BAV group (73 versus 93 min, \( p < 0.001 \); Fig. 1), as was the median fluoroscopy time (7 versus 11 min, \( p < 0.001 \); Fig. 1), and fewer patients in the no-BAV group received catecholamines (9.0% versus 17.9%, \( p = 0.016 \); aOR 0.56; 95% CI 0.24–1.38) (Tables 2 and 3).

**Procedural efficacy**

The device success rate was high and did not differ significantly between groups (Table 2). The rate of device malfunctions was 0.3% in the no-BAV group versus 0.6% in the BAV groups (\( p = 0.616 \)), although the adjusted odds ratio of 0.02 (95% CI 0.01–0.74) suggested the risk was reduced in the no-BAV group. Mean pressure gradients decreased from 41 to 9 mmHg in the no-BAV group and from 43 to 9 mmHg in the BAV group. Among procedural complications, atrioventricular block was significantly less common in the no-BAV group than the BAV group (1.4%...
versus 4.1%, \( p = 0.035 \); however, although the unadjusted odds ratio supported a reduced risk in the no-BAV group (OR 0.33, 95% CI 0.11–0.88), this was no longer significant in the adjusted analysis (aOR 0.44, 95% CI 0.12–1.38) (Table 3). Most patients had no paravalvular leakage after the procedure (no-BAV 84.3%; BAV 78.5%); moderate/severe paravalvular regurgitation was less common in the no-BAV group than the BAV group (\( p = 0.001 \); Table 2). There were no significant differences between groups for other procedural complications.

### 30-day outcomes

There were no significant between-group differences in the rate of death (Fig. 2), stroke, permanent pacemaker

#### Table 2 Procedural data and outcomes

|                | TAVI with BAV | TAVI without BAV | \( p \)-value |
|----------------|---------------|------------------|--------------|
| Valve size     |               |                  |              |
| 20–23 mm       | 28.9          | 31.0             | < 0.001      |
| 26 mm          | 45.1          | 41.1             |              |
| 29 mm          | 26.0          | 27.9             |              |
| Post-delivery balloon dilation (%) | 339 22.4 | 355 15.5 | 0.020 |
| Quantity contrast agent used (mL) | 303 100 (73–131) | 349 95 (70–126) | 0.343 |
| Access complications (%) | 339 0.9 | 355 2.3 | 0.224 |
| Hemodynamic instability (%) | 117 5.1 | 277 2.5 | 0.219 |
| Catecholamine use (inotropes) (%) | 117 17.9 | 277 9.0 | 0.016 |
| Effective orifice area post-surgery | 119 1.89 (1.59/2.30) | 114 1.80 (1.50/2.20) | 0.378 |
| Indexed effective orifice area | 282 0.38 (0.31/0.46) | 251 0.39 (0.31/0.46) | 0.348 |
| AV mean PG post-surgery | 286 9.0 (6.0/12.0) | 252 9.0 (6.0/12.8) | 0.862 |
| Paravalvular regurgitation | 339 78.5 | 351 84.3 | < 0.001 |
| None/trace     |               |                  |              |
| Mild           | 18.9          | 15.1             |              |
| Moderate       | 2.4           | 0.6              |              |
| Severe         | 0.3           | 0.0              |              |
| Device success (%) | 339 97.9 | 355 99.2 | 0.214 |
| Second valve needed (%) | 339 1.2 | 355 0.8 | 0.719 |
| Conversion to surgery (%) | 141 3.5 | 280 2.1 | 0.518 |
| Coronary artery obstruction requiring intervention (%) | 213 0.9 | 71 0.0 | 1.000 |
| Device malfunction (%) | 339 0.6 | 355 0.3 | 0.616 |
| Atrioventricular block (%) | 339 4.1 | 355 1.4 | 0.035 |
| Aortic root rupture (%) | 339 0.3 | 355 0.0 | 0.488 |
| Correct positioning of a single prosthetic valve into the proper anatomical location | 339 99.1 | 351 99.7 | 0.363 |
| Intended performance of the prosthetic valve | 287 97.9 | 217 98.6 | 0.738 |

Values are median (interquartile range) unless indicated otherwise

AV Aortic valve, BAV Balloon aortic valvuloplasty, CI Confidence interval, OR Odds ratio, PG Pressure gradient, TAVI Transcatheter aortic valve implantation

#### Table 3 Procedural data and outcomes

|                | TAVI with BAV | TAVI without BAV | Adjusted OR* (95% CI) |
|----------------|---------------|------------------|----------------------|
| Post-delivery balloon dilation (%) | 22.4 | 15.5 | 0.63 (0.43–0.93) |
| Catecholamine use (Use of inotropes) (%) | 17.9 | 9.0 | 0.45 (0.24–0.85) |
| Atrioventricular block (%) | 4.1 | 1.4 | 0.33 (0.11–0.88) |
| Correct positioning of a single prosthetic valve into the proper location (%) | 99.1 | 99.7 | 3.16 (0.4–64.07) |
| Intended performance of the prosthetic valve (%) | 97.9 | 98.6 | 2.11 (0.55–10.08) |

*data were adjusted for age, gender, prior MI, stroke / TIA, creatinine, ejection fraction and NYHA class

\BAV Balloon aortic valvuloplasty, CI Confidence interval, OR Odds ratio, TAVI Transcatheter aortic valve implantation
implantation or other outcomes at day 30 (Table 4), with the exception of patients in the no-BAV group being less likely in NYHA class III/IV than those in the BAV group (17.6% versus 54.5%; aOR 0.18, 95% CI 0.12–0.27).

Outcomes by access route
Outcomes for patients receiving TAVI with or without BAV according to the access route are summarized in Table 5 (procedural outcomes) and Table 6 (30-day outcomes). The need for post-delivery balloon dilation was reduced in the no-BAV group compared with the BAV group among TF-TAVI patients (OR 0.43, 95% CI 0.21–0.89) but not TA-TAVI or TAo-TAVI patients (Table 5). Total procedure time was reduced in the no-BAV group compared with the BAV only among TF-TAVI patients (56.5 versus 89.5 min, p < 0.001) and not among TA-TAVI or TAo-TAVI patients (Fig. 1), whereas fluoroscopy time was reduced in the no-BAV group for all access routes (Fig. 1). The quantity of contrast agent used was reduced in the no-BAV group only among patients undergoing TAo-TAVI (80 versus 94 mL, p = 0.008). Use of inotropes was reduced in the no-BAV group only among patients undergoing TA-TAVI (17.5% versus 32.8%; OR 0.44, 95% CI 0.22–0.87). Most patients had no paravalvular regurgitation after TAVI irrespective of the use of BAV and route of access (76.6–86.0%). Moderate/severe paravalvular regurgitation appeared to be more common in the BAV group than the no-BAV group among those who underwent TAo-TAVI (Table 5).

No significant differences in 30-day outcomes between the no-BAV and BAV groups were seen in the analysis by route of access (Table 6) except for a reduced likelihood of being in NYHA Class III/IV in the no-BAV group treated with TAo-TAVI (60.3% versus 80.6%; OR 0.36, 95% CI 0.21–0.64).

Discussion
This meta-analysis of three prospective multicenter registry studies confirmed that omission of the BAV pre-dilation step prior to TAVI using the balloon-expandable Edwards SAPIEN 3 (or XT) transcatheter heart valve had no adverse effect on procedural or 30-day and 6 months outcomes. On the contrary, it was associated with shorter procedure times and less PVL. The results suggest that BAV is unnecessary in the majority of patients undergoing TF-TAVI, TA-TAVI or TAo-TAVI.

Patient and disease characteristics
Patients in the BAV group were more likely to have peripheral artery disease whereas those in the no-BAV group were more likely to have undergone previous cardiovascular interventions and had a higher EUROSCORE II score. Specific aortic valve-related disease characteristics were generally similar between the groups. The reasons that clinicians selected conventional or direct TAVI were not evaluated in the meta-analysis. One of the individual studies reported that common reasons for omitting BAV were a desire to reduce procedural duration and a perceived risk of cerebral microemboli. Common reasons for performing BAV included to facilitate crossing the native aortic valve and doubts about the choice of valve size [17] (Schymik G, Rudolph TK, Jacobshagen C, Rothe J, Treede H, Kerber S, Frank D, Sykorova L, Okamoto M, Thoenes M, et al. Balloon-expandable transfemoral transcatheter aortic valve implantation with or without pre-dilation – findings from the EASE-IT TF multicentre registry, submitted).
Periprocedural data

As would be expected, omitting the BAV step led to a significantly shorter total procedural time (by approximately 20 min compared with the procedure including BAV). Fluoroscopy time was also shorter in the no-BAV group (by 5 min), although the quantity of contrast agent used was not reduced significantly. A previous meta-analysis of clinical studies also found that procedural time was reduced by approximately 20 min with the omission of BAV; that analysis found no difference in fluoroscopy time but did report reduced use of contrast medium [12].

It might be expected that there would be a potentially greater need for post-procedural dilation in the group that did not undergo pre-dilation, as seen in one previous registry study where the rate was 26% in the no-BAV group compared with 6% in the BAV group [10]. However, in the current meta-analysis post-delivery balloon dilation was less common in the no-BAV group.
than in the BAV group, driven largely by TF-TAVI patients. Other meta-analyses of clinical studies found no significant difference in post-procedural dilation between BAV and non-BAV groups [11, 12].

The rate of device success in the current meta-analysis was high regardless of whether or not BAV was performed, and did not differ significantly between the groups, which is consistent with other registry studies [9, 14] and meta-analyses of clinical studies [11, 12]. However, the adjusted analysis in the current meta-analysis suggested that omission of BAV was associated with a reduced risk of device malfunction. Overall, these results suggest that decisions not to perform BAV were appropriate for patients actually selected for this approach. Of note, the percentage of TAVR procedures without BAV increased over time in the three analyzed studies which might be mainly attributed to the increasing experience of operators and growing evidence that omitting BAV is not disadvantageous in the overall TAVR procedure.

Periprocedural complications
Patients undergoing TAVI and/or BAV can develop arrhythmias, coronary obstruction or severe aortic regurgitation which may necessitate the use of catecholamines. In the current meta-analysis, the need for catecholamine use was reduced when BAV was omitted. In addition, the risk of atrioventricular block was lower when BAV was omitted, although this relationship was no longer significant when the analysis was fully adjusted. Moderate/severe paravalvular regurgitation after TAVI was uncommon in either group, but it appeared to be more common in the BAV group than the no-BAV group among those who underwent TAo-TAVI.

Early safety/efficacy
The current meta-analysis found no significant differences between the BAV and no-BAV groups in terms of the risk of mortality, stroke, permanent pacemaker implantation or other clinical outcomes at 30 days after TAVI, with one excepton. TAVI without BAV was associated with a reduced risk of the patient being in NYHA class III/IV at day 30, which remained significant in the adjusted analysis. The proportion of patients in NYHA class III/IV at baseline did not differ between the groups. The reason for this finding is not clear, but it may relate to the fact that in the initially conducted studies (ROUTE and EASE-it TA) patients were mainly treated with BAV whereas in the latter trial (EASE-it TF) the majority of patients underwent TAVR without BAV. When analyzing these studies together the access route might be the main driver for worse outcome regarding NYHA class, since non-TF treated patients would be expected to undergo a longer recovery period. Other meta-analyses of clinical studies have not reported differences in NYHA class at day 30 [11, 12].

Limitations
The non-randomized nature of the registry studies makes them susceptible to bias. The decision about whether or not to perform BAV was made by the treating clinician and may have been determined by the severity of illness, complexity of the valve anatomy and their perception of the likelihood of successful implantation; thus, it is possible that BAV might have been selected for more complex cases. The procedures being evaluated are subject to a learning curve and less

| Table 4 Outcomes at 30 days | TAVI with BAV | TAVI without BAV | OR (95% CI) |
|-----------------------------|--------------|-----------------|-------------|
|                             | N  | %   | N  | %   | Not-adjusted | Adjusted* |
| Death (%)                   | 327| 1.8 | 343| 1.5 | 0.79 (0.23–2.65) | 0.4 (0.06–1.86) |
| Stroke (%)                  | 327| 0.9 | 341| 0.3 | 0.32 (0.02–2.5)  | 0.79 (0.02–27.7) |
| Non-fatal MI (%)            | 336| 0.6 | 349| 0.9 | 1.45 (0.24–11.05) | 1.29 (0.12–13.1) |
| New-onset dialysis (%)      | 332| 3.9 | 348| 3.7 | 0.95 (0.43–2.1)  | 0.97 (0.4–2.32)  |
| Creatinine increase (%)     | 268| 1.5 | 210| 1.4 | 0.96 (0.19–4.38) | 0.42 (0.02–3.22) |
| Permanent pacemaker implantaion (%) | 337| 10.1 | 350| 8.6 | 0.84 (0.5–1.4)  | 1.17 (0.62–2.2)  |
| Life-threatening bleeding (%)| 333| 3.0 | 345| 1.4 | 0.48 (0.15–1.35) | 0.42 (0.09–1.48) |
| Major vascular complications (%) | 333| 4.5 | 345| 3.5 | 0.76 (0.35–1.66) | 0.63 (0.21–1.65) |
| Hospitalization (%)         | 333| 2.7 | 344| 1.2 | 0.42 (0.11–1.31) | 0.48 (0.09–1.9)  |
| Valve dysfunction (%)       | 322| 0.9 | 337| 0.0 | –              | –             |
| NYHA Class III or IV (%)    | 336| 54.5| 346| 17.6| 0.18 (0.13–0.25) | 0.18 (0.12–0.27) |
| CCS grading of angina pectoris Class III or IV (%) | 308| 1.6 | 296| 1.0 | 0.62 (0.13–2.55) | 0.98 (0.18–4.8) |

BAV Balloon aortic valvuloplasty, CI Confidence interval, CCS Canadian cardiovascular society, MI Myocardial infarction, NYHA New York Heart Association, OR Odds ratio, TAVI Transcatheter aortic valve implantation
*a data were adjusted for age, gender, prior MI, stroke / TIA, creatinine, ejection fraction and NYHA class

Ashauer et al. BMC Cardiovascular Disorders (2019) 19:172
Page 7 of 10
experienced surgeons/teams might have been more likely to perform BAV. However, the meta-analysis was adjusted for potential confounders where possible. All three studies evaluated balloon-expandable Edwards SAPIEN valves (primarily the SAPIEN 3), which reduced confounding associated with the use of different devices; however, the results therefore do not necessarily apply to TAVI performed using other transcatheter valve

Table 5 Procedural outcomes by access route

|                        | TF access | TA access | TAo access |
|------------------------|-----------|-----------|------------|
| **Valve size**         |           |           |            |
| 20–23 mm               | 37.5 /    | 29.5 /    | 26.6 /     |
|                        | 31.4      | 30.7      | 30.8       |
| 26 mm                  | 23.2 /    | 49.2 /    | 49.5 /     |
|                        | 39.3      | 40.9      | 44.9       |
| 29 mm                  | 39.3 /    | 21.3 /    | 23.9 /     |
|                        | 29.3      | 28.5      | 24.4       |
| **Quantity contrast agent used (mL)** | 131 / 120 | 85 / 80 | 94 / 80 | 0.008 |
| **Effective orifice area post-surgery** | 1.40 | 2.10 | 1.80 | 0.809 |
|                        | 1.65      | 2.00      | 1.82       |
| **Indexed effective orifice area** | 0.71 | 1.17 | 1.04 | 0.857 |
|                        | 0.87      | 1.04      | 1.00       |
| **AV mean PG post-surgery** | 12 / 11 | 4 / 5 | 9 / 10 | 0.863 |
| **Paravalvular regurgitation** | 0.001 | < 0.001 | < 0.001 |
|                        |           |           |            |
| **Access complications (%)** |          |           |            |
|                        |           |           |            |
| **Hemodynamic instability (%)** | 3.6 / 0.7 | 6.6 / 4.4 | 0.65 (0.18–2.63) | n.c. |
|                        |           |           |            |
| **Catecholamine use (%)** | 1.8 / 0.7 | 3.28 / 17.5 | 0.44 (0.22–0.87) | n.c. |
|                        |           |           |            |
| **Device success (%)** | 92.9 / 98.6 | 100 / 100 | 98.6 / 98.7 | 0.95 (0.05–7.53) |
|                        |           |           |            |
| **Second valve needed (%)** | 0 / 0.7 | 0 / 0 | 1.8 / 2.6 | 0.7 (0.13–5.1) |
|                        |           |           |            |
| **Conversion to surgery (%)** | 0 / 2.9 | 0 / 1.5 | 1.7 / 0 | n.a. |
|                        |           |           |            |
| **Device malfunction (%)** | 0 / 0 | 0 / 0.7 | 0.9 / 0 | n.a. |
|                        |           |           |            |
| **Atrioventricular block (%)** | 3.6 / 2.1 | 1.6 / 1.5 | 0.89 (0.08–19.34) | 5 / 0 | n.a. |
|                        |           |           |            |
| **Aortic root rupture (%)** | 0 / 0 | n.a. | 0.5 / 0 | n.a. |
|                        |           |           |            |
| **Correct positioning of a single prosthetic valve into the proper anatomical location (%)** | 100 / 100 | 100 / 100 | 98.6 / 98.7 | 1.05 (0.13–21.5) |
|                        |           |           |            |
| **Intended performance of the prosthetic valve (%)** | 92.9 / 98.6 | 100 / 100 | 99.1 / 98.7 | 0.7 (0.07–15.2) |

Values are median (interquartile range) unless indicated otherwise
AV = Aortic valve, CI = Confidence interval, n.a. Not applicable (e.g. no ratio), n.c. Data not collected, OR = Odds ratio, PG = Pressure gradient, TA = Transapical, TAo = Transaortic, TF = Transfemoral, Xw = Transcatheter aortic valve implantation with balloon aortic valvuloplasty, Xwo = TAVI Transcatheter aortic valve implantation without balloon aortic valvuloplasty

experienced surgeons/teams might have been more likely to perform BAV. However, the meta-analysis was adjusted for potential confounders where possible. All three studies evaluated balloon-expandable Edwards SAPIEN valves (primarily the SAPIEN 3), which reduced confounding associated with the use of different devices; however, the results therefore do not necessarily apply to TAVI performed using other transcatheter valve
systems. When analyzed by route of access, there were too few 30-day outcome events to allow a meaningful interpretation.

**Conclusions**

This meta-analysis of real-world data indicates that TAVI performed without BAV is advantageous as it has a high device success rate, reduced procedure and fluoroscopy time, reduced risk of PVL and no adverse effect on short-term clinical outcomes.

**Abbreviations**

aOR: Adjusted odds ratio; BAV: Balloon aortic valvuloplasty; OR: Odds ratio; PV: Paravalvular; TF: Transfemoral; TA: Transapical; TAo: Transaortic; TAVI: Transcatheter aortic valve implantation

**Authors’ contributions**

JOA, NB, MK, GS, CB, MR, VB, JS, HS, AB, CD, PB, JK, MT, SB and TR were involved in the conception and design of the analysis. NB, MK, MR and VB (ROUTE), JS and HS (EASE-IT TA), SB, CB and GS (EASE-IT TF) are the principal investigators of the single registries or key centers. AB and CD were responsible for the statistical analysis. JOA, PB, and TR wrote the first draft of the manuscript which all authors (JOA, NB, MK, GS, CB, MR, VB, JS, HS, AB, CD, PB, JK, MT, SB and TR) revised it for important intellectual content. All authors have given final approval of the version to be published.

**Funding**

A research grant was provided by Edwards Lifesciences, Nyon, Switzerland to IPPMed. MT and JK, as representatives of the funder, contributed, as the other authors, to the overall development of the manuscript (see below). They had an equal vote during the discussion of conflicting comments but no veto right.

**Table 6 Outcomes at 30 days by access route**

| Outcome                      | TF access | TA access | TAo access |
|------------------------------|-----------|-----------|------------|
| Xw/Xwo OR (95%CI)            | Xw/Xwo OR (95%CI) | Xw/Xwo OR (95%CI) |
| Death (%)                    | 0 / 1.4 n.a. | 0 / 0.8 n.a. | 2.8 / 2.8 1 (0.14–4.46) |
| Stroke (%)                   | 0 / 0 n.a. | 0 / 0 n.a. | 1.4 / 1.4 0 (0.05–7.95) |
| Non-fatal MI (%)             | 0 / 0.7 n.a. | 1.6 / 0.7 0.44 (0.05–11.28) | 0.5 / 1.4 2.99 (0.12–76.16) |
| New onset dialysis (%)       | 0 / 0 n.a. | 4.9 / 5.1 1.04 (0.25–4.96) | 9.2 / 10.3 1.13 (0.23–4.66) |
| Creatinine increase (%)      | 0 / 1.4 n.a. | – | 1.9 / 1.4 0.74 (0.04–5.13) |
| PPI (%)                      | 8.9 / 7.2 0.79 (0.27–2.64) | 14.8 / 10.2 0.66 (0.27–1.67) | 9.1 / 8.1 0.88 (0.31–2.17) |
| Life-threatening bleeding (%) | 1.8 / 1.4 n.a. | 1.7 / 0.8 0.44 (0.02–11.13) | 3.7 / 2.7 0.73 (0.11–3.01) |
| Major vascular complications (%) | 10.7 / 5.8 0.51 (0.17–1.61) | 1.7 / 1.5 0.88 (0.08–19.09) | 3.7 / 2.7 0.73 (0.11–3.01) |
| Hospitalization (%)          | 1.8 / 0.7 0.40 (0.02–10.27) | 1.7 / 0 n.a. | 3.2 / 4.1 1.28 (0.27–4.74) |
| Valve dysfunction (%)        | 0 / 0 n.a. | 0 / 0 n.a. | 1.4 / 0 n.a. |
| NYHA Class III or IV (%)     | 5.04 / 8.1 1.55 (0.46–7.08) | 1.7 / 2.3 1.33 (0.17–27.11) | 80.6 / 60.3 0.36 (0.21–0.64) |
| CCS III or IV (%)            | 0 / 0 n.a. | 0 / 0 n.a. | 2.5 / 6.4 2.62 (0.52–11.08) |

**Values are median (interquartile range) unless indicated otherwise**

**Availability of data and materials**

Available from the corresponding author upon reasonable request.

**Ethics approval and consent to participate**

All three studies included in the meta-analysis were multicenter, prospective, observational registry studies conducted under the guidance of the Institute for Pharmacology and Preventive Medicine (Cloppenburg, Germany). Full details of the design and methodology for each study have been reported previously [18–20]. Ethical approval for each study and written patient informed consent was obtained.

**Consent for publication**

Not applicable.

**Competing interests**

NB, MR, VB, JS, HS, CS, GS, SB and TR have received consultancy fees from different companies producing heart valves. JK and MT are employees of Edwards Lifesciences. PB is the representative of the Institute for Pharmacology and Preventive Medicine, Cloppenburg (IPPMed), Germany. AB is a consultant for IPPMed. CD, JOA, and MK declare no conflicts of interest.

**Author details**

1Department of Cardiology, University of Cologne Heart Center, Cologne, Germany. 2Department of Cardiac Surgery, Medical University Innsbruck, Innsbruck, Austria. 3Medical Clinic IV, Department of Cardiology, Municipal Hospital, Karlsruhe, Germany. 4Department of Cardiology, Immanuel Clinic Bernau, Heart Center Brandenburg, Bernau, Germany. 5Institut Hospitalier Jacques Cartier, Massy, France. 6Columbia University Medical Center / New York Presbyterian Hospital, New York, NY, USA. 7Clinic for Cardiosurgery and Thoracic Surgery, Berufsgenossenschaftliches Universitätsklinikum Bergmannsheil, Bochum, Germany. 8Department Cardiovascular Surgery, University Heart Center Freiburg, Bad Krozingen, Germany. 9Healthtwist GmbH, Berlin, Germany. 10Institute for Pharmacology and Preventive Medicine, Bahnhofstrasse 20, 49661 Cloppenburg, Germany. 11Edwards Lifesciences, Medical Affairs/Professional Education, Prague, Czech Republic. 12Edwards Lifesciences, Medical Affairs/Professional Education, Nyon, Switzerland. 13Department of Cardiology, Heart and Diabetes Center Bad Oeynhausen, Ruhr-University of Bochum, Bad Oeynhausen, Germany.
References

1. Walther T, Dewey T, Borger MA, Kemptpf J, Linke A, Becht R, Falk V, Schuler G, Mohr FW, Mack M. Transapical aortic valve implantation: step by step. Ann Thorac Surg. 2009;87(1):276–83.

2. Patalis PC, Al-Rashid F, Neumann T, Plicht B, Hildebrandt HA, Wendt D, Thielmann M, Jakob HG, Heusch G, Erbel R, et al. Preparatory balloon aortic valvuloplasty during transcatheter aortic valve implantation for improved sizing. JACC Cardiovasc Interv. 2013;6(9):965–71.

3. Grube E, Naber C, Abizaid A, Sousa E, Mendiz O, Lemos P, Kaill Filho R, Mangione J, Buellesfeld L. Feasibility of transcatheter aortic valve implantation without balloon pre-dilation: a pilot study. JACC Cardiovasc Interv. 2011;4(7):751–7.

4. Vahanian A, Himbert D. Transcatheter aortic valve implantation: could it be done without prior balloon valvuloplasty? JACC Cardiovasc Interv. 2011;4(7):758–9.

5. Ben-Dor I, Pichard AD, Satler LF, Goldstein SA, Syed AI, Gaglia MA Jr, Weissman G, Maluenda G, Gonzalez MA, Kakababu K, et al. Complications and outcome of balloon aortic valvuloplasty in high-risk or inoperable patients. JACC Cardiovasc Interv. 2010;3(11):1150–6.

6. Erdos G, Basciani R, Huber C, Stortecky S, Wennegger P, Windecker S, Carrel T, Eberle B. Transcranial Doppler-detected cerebral embolic load during transcatheter aortic valve implantation. Eur J Cardiothorac Surg. 2012;41(4):778–83 discussion 773–774.

7. Gensas CS, Caixeta A, Siqueira D, Carvalho LA, Sarmento-Leite R, Mangione JA, Lemos PA, Colfranceschi AS, Caramori P, Ferreira MC, et al. Predictors of permanent pacemaker requirement after transcatheter aortic valve implantation: insights from a Brazilian registry. Int J Cardiol. 2014;175(2):248–52.

8. Drews T, Pasch M, Buz S, Unbehaun A, Dreyse S, Kukucka M, Mladenow A, Hetzer R. Transcranial Doppler sound detection of cerebral microembolism during transapical aortic valve implantation. Thorac Cardiovasc Surg. 2011;59(4):237–42.

9. Deharo P, Jaussaud N, Grisoli D, Camus O, Resseguier N, Le Breton H, Auffret V, Regueiro A, Campelo-Parada F, Del Trigo M, Chiche O, Chamandi A, de Belder MA, Sponga S, Assa H, Halkin A, Fefer P, Ben-Shoshan J, et al. Balloon dilatation and meta-analysis. Catheter Cardiovasc Interv. 2017;90(5):839.

10. Butter C, Okamoto M, Schymik G, Jacobshagen C, Rothe J, Treede H, Kerber S, Frank D, Bramlage P, Sykorova L, et al. Degree of valve calcification in patients undergoing transfemoral transcatheter aortic valve implantation with and without balloon aortic valvuloplasty: findings from the multicenter EASE-IT TF registry. Catheter Cardiovasc Interv. 2019. https://doi.org/10.1002/ccd.28164. Epub ahead of print.

11. Bagur R, Kwok CS, Nombela-Franco L, Ludwig PF, de Belder MA, Sponga S, Gunning M, Nolan J, Diamantouros P, Teefy PJ, et al. Transcatheter aortic valve implantation without balloon aortic valvuloplasty on procedural and clinical outcomes: insights from the FRANCE TAVI registry. JACC Cardiovasc Interv. 2018;11(19):1956–60.

12. Kappetein AP, Head SJ, Genevreux P, Piazza N, van Mieghem NM, Blackstone EH, Brott TG, Cohen DJ, Gurfinkel DE, van ES GA, et al. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the valve academic research Consortium-2 consensus document (VARC-2). Eur J Cardiothorac Surg. 2012;42(5):S45–60.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.